Intercept Pharmaceuticals Escalates +289.37% on FLINT Premature Conclusion (NASDAQ:ICPT), Conatus Pharmaceuticals Inc (NASDAQ:CNAT), Magnegas Corporation (NASDAQ:MNGA)

While senior earnings analyst speculate the S&P 500 earnings growth rate at 6.3% for the 4th quarter, we would advise you to take a look at Intercept Pharmaceuticals, Inc. ticker symbol (NASDAQ:ICPT). Intercept Pharmaceuticals, Inc. has surged +289.37% Up 209.47 generating over four point six million shares in the financial market at $281.86 per share Thursday January 9, 2014 Real-time: 11:37AM EST. The Comany (www.interceptpharma.com) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver diseases utilizing its expertise in bile acid chemistry. The topic of interest amongst investors surrounding Intercept Pharmaceuticals, Inc. is its FLINT trial of obeticholic acid for the treatment of nonalcoholic steatohepatitis.

Long story short, the FLINT trial has been concluded early for efficacy based on a decision and arrange in advance interim analysis showing that the primary endpoint of the trial has been met. The unanticipated early stopping of the FLINT trial indicates the significance of FLINT with its major milestone. The global market for drugs used to treat liver disease is expected to reach US$14.2 billion by 2016.

On a different note, take a look at ticker symbol (NASDAQ:CNAT). Conatus Pharmaceuticals Inc. has surged +115.22% Up 7.19 generating over one point four million shares in the financial market at $13.43 per share Thursday January 9, 2014 Real-time: 11:54AM EST. The Comany (www.conatuspharma.com) is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. The topic of interest amongst investors surrounding Conatus Pharmaceuticals Inc. is its emricasan. The product emricasan was developed for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals Inc. previously received U.S. FDA Orphan Drug Designation for Emricasan for treatment of liver transplant recipients with reestablished fibrosis.

Another ticker symbol that need not be over looked is (NASDAQ:MNGA). Magnegas Corporation has surged +105.94% Up 1.07 generating over five point seven million shares in the financial market at $2.08 per share Thursday January 9, 2014 Real-time: 12:01PM EST. The Comany (www.magnegas.com) is the developer of a technology that converts liquid waste into hydrogen-based fuels. The topic of interest amongst investors surrounding Magnegas Corporation is that its Nuova MagneGas Italia inked a contract to perform tests on MagneGas fuels. Magnegas Corporation expect that this will hurry the validated consenting of its MagneGas fuels.

Read Full Disclaimer at http://crweselect.com/disclaimer/

Remember: Always do your homework and consult your own financial professional.